A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery

Purpose

The researchers are doing this study to see if treating people's brain tumors with stereotactic radiosurgery (SRS) before tumor resection surgery will prevent cancer cells from spreading to other areas of the brain, including the fluid and lining around the brain, during surgery, and lead to better surgical outcomes and fewer complications after surgery (post-surgery complications). Only one brain tumor (the index tumor) will be treated with the study radiosurgery and then removed by surgery. If there are other brain tumors, they will not be removed by surgery in this study, although they may be treated separately with standard radiation if the doctor decides it is needed.

Condition

  • Brain Metastasases

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically or cytologically confirmed breast cancer, non-small cell lung cancer, melanoma, or gastrointestinal cancer. In malignancies for which tissue confirmation is not standard diagnostic practice (for example, hepatocellular carcinoma diagnosed by characteristic imaging), radiographic diagnosis consistent with standard of care is acceptable. In all cases, the intracranial lesion planned for resection undergoes pathologic examination as part of protocol-directed surgery. - At least one intact brain metastasis is planned for surgical resection that has not previously received stereotactic radiosurgery or other focal radiotherapy, measuring 6 cm or less in diameter. - No evidence of leptomeningeal disease based on clinical symptoms, MRI imaging of the brain or spinal cord, and/or lumbar puncture cytologic analysis. - No prior SRS to the index BM planned for surgical resection. Prior SRS to non- index lesions is permitted, with approval from the principal investigator. The interval since prior cranial radiotherapy will be recorded. All clinically significant toxicities from prior radiotherapy must have resolved to grade 1 or lower (CTCAE); patients with unresolved symptomatic (grade 2 or higher) radiation necrosis, treatment-related enhancing treatment effect, or clinically significant cerebral edema attributable to prior cranial radiation are not eligible. - No prior therapeutic craniotomy or craniectomy with biopsy. - Age ≥ 18 - Karnofsky Performance Status (KPS) of ≥ 70 and anticipated survival of >1 year - Ability to undergo contrast-enhanced MRI brain

Exclusion Criteria

  • Pregnant and/or breastfeeding - Prior whole brain radiotherapy. - Neurologic instability despite medical management, such that either the treating team or study investigators feel that urgent craniotomy without awaiting SRS is indicated. - Judgment by the principal investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Stereotactic RadioSurgery
Patients will be seen by an attending radiation oncologist before receiving SRS. Standard of are history and physical will be obtained. An MRI brain with contrast will be performed within seven days of the CT simulation for SRS planning. Surgical resection of the index lesion is to be performed within 10 days of SRS, and no later than 21 days to accommodate operating room availability.
  • Radiation: Stereotactic Radiosurgery
    Stereotactic Radiosurgery (SRS) to the index lesion will be delivered with standard of care technique at doses of 18Gy or 21Gy, for tumors >3cm and ≤3cm, respectively, in a single fraction.
  • Procedure: Surgical Resection
    Patients will undergo standard-of-care surgical resection of the index lesion within 10 days of SRS, and no later than 21 days to accommodate operating room availability.

Recruiting Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey 07920
Contact:
Luke Pike, MD
212-639-8157

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey 07748
Contact:
Luke Pike, MD
212-639-8157

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey 07645
Contact:
Luke Pike, MD
212-639-8157

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York 11725
Contact:
Luke Pike, MD
212-639-8157

Memorial Sloan Kettering Westchester (Limited Protocol Activities)
East White Plains, New York 10604
Contact:
Luke Pike, MD
201-775-7604

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York 10065
Contact:
Luke Pike, MD
201-775-7604

Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Rockville Centre, New York 11553
Contact:
Luke Pike, MD
212-639-8157

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Luke Pike, MD, PhD
212-639-8157
pikel@mskcc.org